Subtype
Anorectal Neoplasm
CI-CAN-00001814Explore in graph →
Non-malignant504 active trials1 approved drugs6 evidence items
- NCIt
- C215222
Loading cancer entity…
Subtype
CI-CAN-00001814Explore in graph →
Clinical trials
2,046 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04719988 | Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.(INTERACT-ION) | active not recruiting | Phase 2 | 55 | Centre Hospitalier Universitaire de Besancon |
| 1 |
| Dec 20, 2024 |
| clinicaltrials |
| NCT03840239 | TNT to Increase the Clinical Complete Response Rate for Distal LARC(TESS) | active not recruiting | Phase 2 | 98 | Sun Yat-sen UniversityOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT03391843 | Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer | active not recruiting | Phase 2 | 100 | RenJi HospitalOTHER | 1 | Jan 5, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Mar 21, 2025source: clinicaltrials